Dr. Burt Adelman was most recently Executive Vice President Research and Development and Chief Medical Officer at Dyax Corp. He joined Dyax in February of 2012. In January 2016 Dyax was sold to Shire Pharma. In 1991, Dr. Adelman joined Biogen in Cambridge, MA. While at Biogen Dr. Adelman held various positions including Medical Director, Vice President Regulatory Affairs, Executive Vice President of Research and Development and Executive Vice President for Portfolio Strategy. During this period, Dr. Adelman led development efforts for Angiomax (bivalarudin) for anticoagulation during angioplasty (sold by the Medicines Company), Avonex (interferon beta) for multiple sclerosis, Amevive (alefecept) for psoriasis, and Tysabri (natalizumab) for multiple sclerosis. Dr. Adelman’s experience and expertise in drug development spans from discovery to development to commercial promotion and includes biologics and small molecules. Dr. Adelman retired from Biogen in December 2007. During 2010 and 2011, Dr. Adelman served as interim President of Research and Development at Eleven Biotherapeutics. Currently, Dr. Adelman serves as a board member for Catabasis Pharmaceuticals, Sirona-med (a private cardiac device company) and Syntimmune (a private immune disease company), and is an advisor to Voyager Therapeutics. Dr. Adelman also is a member of the Tufts Medical School Board of Overseers and a member of the investment committee of the Partners Innovation Fund (Mass General and Brigham and Women’s Hospitals). Dr. Adelman is a frequent juror for the Lemelson Prize Program at MIT a member of the Corporation of Partners Healthcare and a currently on the faculty of MIT and the Harvard Medical School. Dr. Adelman graduated Cornell University Medical College in 1976, served as House Officer and Medical Resident at the Peter Bent Brigham Hospital and completed his hematology fellowship at the Brigham in 1981.